

## Tafinlar (dabrafenib) Prior Authorization Request Form



**Caterpillar Prescription Drug Benefit** 

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI\_DISCLOSURE\_AUTHORIZATION.PDF</u>

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_\_

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY		IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):				

Continued on next page.









MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHEI	R MEDICATIONS FOR THIS CONDITION	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
🗆 Melanoma	ICD-10 Code(s):			
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINI	CAL INFORMATION TO SUPPORT A		
Does the patient have a diagnosis of u Is the patient BRAF V600E or BRAF V60 *Please provide documentation Does the patient have wild-type BRAF		□ Yes □ No		
Has the patient previously received treatment with Zelboraf (vemurafenib)?   Yes  No				
Has the patient previously received treatment with Mekinist (trametinib) monotherapy? $\square$ Yes $\square$ No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received. ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical				
	uracy of the information reported on the	•		
Prescriber Signature or Electronic I.D.	Verification:	Date:		
<b>CONFIDENTIALITY NOTICE:</b> The documents accur you are not the intended recipient, you are here	ompanying this transmission contain confidentia eby notified that any disclosure, copying, distrib have received this information in error, please r	ution, or action taken in reliance on the contents		
FAX THIS FORM TO: 800-424-7640				
MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program				

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



